# Acadia Healthcare Company, Inc.: financial statements, quarterly

ACHC · Nasdaq · CIK 1520697 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/achc.md) · [Financials](/companies/achc/financials.md) · [Filings](/companies/achc/filings.md) · [Insiders](/companies/achc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/achc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [731](/filings/0000950170-24-089248.md) | [750](/filings/0000950170-24-119044.md) | [743 d](/filings/0001193125-26-078266.md) | [768](/filings/0000950170-25-069294.md) | [796](/filings/0000950170-25-103160.md) | [816](/filings/0001193125-25-267062.md) | [774 d](/filings/0001193125-26-078266.md) | [771](/filings/0001193125-26-192508.md) | [869](/filings/0000950170-25-103160.md) | [852](/filings/0001193125-25-267062.md) | [821 d](/filings/0001193125-26-078266.md) | [829](/filings/0001193125-26-192508.md) |
| Operating income | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [22.9](/filings/0000950170-24-089248.md) | [(71.9)](/filings/0000950170-24-119044.md) | [20.2 d](/filings/0001193125-26-078266.md) | [20.1](/filings/0000950170-25-069294.md) | [25.6](/filings/0000950170-25-103160.md) | [27.2](/filings/0001193125-25-267062.md) | [4.5 d](/filings/0001193125-26-078266.md) | [4.4](/filings/0001193125-26-192508.md) | [12.1](/filings/0000950170-25-103160.md) | [1.7](/filings/0001193125-25-267062.md) | [7.8 d](/filings/0001193125-26-078266.md) | [6.5](/filings/0001193125-26-192508.md) |
| Net income | $m | [72.3](/filings/0000950170-24-119044.md) | [(218)](/filings/0000950170-24-119044.md) | [57.7](/filings/0000950170-24-119044.md) | [76.4](/filings/0001193125-25-267062.md) | [78.5](/filings/0001193125-25-267062.md) | [68.1](/filings/0001193125-25-267062.md) | [32.6](/filings/0001193125-25-267062.md) | [8.4](/filings/0001193125-26-192508.md) | [30.1](/filings/0001193125-26-192508.md) | [36.2](/filings/0001193125-26-192508.md) | [(1,178)](/filings/0001193125-26-192508.md) | [4.1](/filings/0001193125-26-192508.md) |
| Diluted EPS | $ per share | [0.79](/filings/0000950170-24-089248.md) | [(2.39)](/filings/0000950170-24-119044.md) | not reported | [0.83](/filings/0000950170-25-069294.md) | [0.85](/filings/0000950170-25-103160.md) | [0.74](/filings/0001193125-25-267062.md) | not reported | [0.09](/filings/0001193125-26-192508.md) | [0.33](/filings/0000950170-25-103160.md) | [0.40](/filings/0001193125-25-267062.md) | not reported | [0.05](/filings/0001193125-26-192508.md) |
| Basic EPS | $ per share | [0.79](/filings/0000950170-24-089248.md) | [(2.39)](/filings/0000950170-24-119044.md) | not reported | [0.84](/filings/0000950170-25-069294.md) | [0.86](/filings/0000950170-25-103160.md) | [0.74](/filings/0001193125-25-267062.md) | not reported | [0.09](/filings/0001193125-26-192508.md) | [0.33](/filings/0000950170-25-103160.md) | [0.40](/filings/0001193125-25-267062.md) | not reported | [0.05](/filings/0001193125-26-192508.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Operating income: not reported
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [112](/filings/0000950170-23-035484.md) | [99.6](/filings/0000950170-23-058814.md) | [100](/filings/0000950170-25-029095.md) | [77.3](/filings/0000950170-24-052085.md) | [77.2](/filings/0000950170-24-089248.md) | [82.1](/filings/0000950170-24-119044.md) | [76.3](/filings/0001193125-26-078266.md) | [91.2](/filings/0000950170-25-069294.md) | [131](/filings/0000950170-25-103160.md) | [119](/filings/0001193125-25-267062.md) | [133](/filings/0001193125-26-192508.md) | [158](/filings/0001193125-26-192508.md) |
| Current assets | $m | [579](/filings/0000950170-23-035484.md) | [703](/filings/0000950170-23-058814.md) | [596](/filings/0000950170-25-029095.md) | [611](/filings/0000950170-24-052085.md) | [645](/filings/0000950170-24-089248.md) | [652](/filings/0000950170-24-119044.md) | [577](/filings/0001193125-26-078266.md) | [639](/filings/0000950170-25-069294.md) | [692](/filings/0000950170-25-103160.md) | [748](/filings/0001193125-25-267062.md) | [814](/filings/0001193125-26-192508.md) | [837](/filings/0001193125-26-192508.md) |
| Total assets | $m | [5,150](/filings/0000950170-23-035484.md) | [5,346](/filings/0000950170-23-058814.md) | [5,359](/filings/0000950170-25-029095.md) | [5,517](/filings/0000950170-24-052085.md) | [5,678](/filings/0000950170-24-089248.md) | [5,870](/filings/0000950170-24-119044.md) | [5,957](/filings/0001193125-26-078266.md) | [6,148](/filings/0000950170-25-069294.md) | [6,308](/filings/0000950170-25-103160.md) | [6,413](/filings/0001193125-25-267062.md) | [5,527](/filings/0001193125-26-192508.md) | [5,546](/filings/0001193125-26-192508.md) |
| Current liabilities | $m | [432](/filings/0000950170-23-035484.md) | [865](/filings/0000950170-23-058814.md) | [886](/filings/0000950170-25-029095.md) | [482](/filings/0000950170-24-052085.md) | [547](/filings/0000950170-24-089248.md) | [610](/filings/0000950170-24-119044.md) | [578](/filings/0001193125-26-078266.md) | [473](/filings/0000950170-25-069294.md) | [524](/filings/0000950170-25-103160.md) | [518](/filings/0001193125-25-267062.md) | [525](/filings/0001193125-26-192508.md) | [489](/filings/0001193125-26-192508.md) |
| Total liabilities | $m | [2,139](/filings/0000950170-23-035484.md) | [2,536](/filings/0000950170-23-058814.md) | [2,471](/filings/0000950170-25-029095.md) | [2,542](/filings/0000950170-24-052085.md) | [2,613](/filings/0000950170-24-089248.md) | [2,724](/filings/0000950170-24-119044.md) | [2,766](/filings/0001193125-26-078266.md) | [2,974](/filings/0000950170-25-069294.md) | [3,085](/filings/0000950170-25-103160.md) | [3,123](/filings/0001193125-25-267062.md) | [3,387](/filings/0001193125-26-192508.md) | [3,378](/filings/0001193125-26-192508.md) |
| Long-term debt | $m | [1,372](/filings/0000950170-23-035484.md) | [1,350](/filings/0000950170-23-058814.md) | [1,343](/filings/0000950170-25-029095.md) | [1,794](/filings/0000950170-24-052085.md) | [1,775](/filings/0000950170-24-089248.md) | [1,805](/filings/0000950170-24-119044.md) | [1,880](/filings/0001193125-26-078266.md) | [2,184](/filings/0000950170-25-069294.md) | [2,247](/filings/0000950170-25-103160.md) | [2,285](/filings/0001193125-25-267062.md) | [2,472](/filings/0001193125-26-192508.md) | [2,494](/filings/0001193125-26-192508.md) |
| Current portion of debt | $m | [23.9](/filings/0000950170-23-035484.md) | [26.6](/filings/0000950170-23-058814.md) | [29.2](/filings/0000950170-25-029095.md) | [61.5](/filings/0000950170-24-052085.md) | [66.6](/filings/0000950170-24-089248.md) | [71.7](/filings/0000950170-24-119044.md) | [76.8](/filings/0001193125-26-078266.md) | [16.3](/filings/0000950170-25-069294.md) | [20.3](/filings/0000950170-25-103160.md) | [24.4](/filings/0001193125-25-267062.md) | [28.4](/filings/0001193125-26-192508.md) | [32.5](/filings/0001193125-26-192508.md) |
| Shareholders' equity | $m | [2,921](/filings/0000950170-24-119044.md) | [2,713](/filings/0000950170-24-119044.md) | [2,782](/filings/0001193125-26-078266.md) | [2,866](/filings/0001193125-25-267062.md) | [2,953](/filings/0001193125-25-267062.md) | [3,032](/filings/0001193125-25-267062.md) | [3,074](/filings/0001193125-26-192508.md) | [3,042](/filings/0001193125-26-192508.md) | [3,078](/filings/0001193125-26-192508.md) | [3,120](/filings/0001193125-26-192508.md) | [1,949](/filings/0001193125-26-192508.md) | [1,958](/filings/0001193125-26-192508.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [164 d](/filings/0000950170-24-089248.md) | [138 d](/filings/0000950170-24-119044.md) | [116 d](/filings/0001193125-26-078266.md) | [(321)](/filings/0000950170-25-069294.md) | [171 d](/filings/0000950170-25-103160.md) | [163 d](/filings/0001193125-25-267062.md) | [117 d](/filings/0001193125-26-078266.md) | [11.5](/filings/0001193125-26-192508.md) | [134 d](/filings/0000950170-25-103160.md) | [73.2 d](/filings/0001193125-25-267062.md) | [(86.3) d](/filings/0001193125-26-078266.md) | [61.5](/filings/0001193125-26-192508.md) |
| Capital expenditure | $m | [90.8 d](/filings/0000950170-24-089248.md) | [128 d](/filings/0000950170-24-119044.md) | [139 d](/filings/0001193125-26-078266.md) | [142](/filings/0000950170-25-069294.md) | [154 d](/filings/0000950170-25-103160.md) | [190 d](/filings/0001193125-25-267062.md) | [203 d](/filings/0001193125-26-078266.md) | [175](/filings/0001193125-26-192508.md) | [168 d](/filings/0000950170-25-103160.md) | [136 d](/filings/0001193125-25-267062.md) | [93.2 d](/filings/0001193125-26-078266.md) | [76.6](/filings/0001193125-26-192508.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [46.9](/filings/0001193125-26-192508.md) | [3.2 d](/filings/0000950170-25-103160.md) | [0.0 d](/filings/0001193125-25-267062.md) | [0.0 d](/filings/0001193125-26-078266.md) | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [91.5](/filings/0000950170-23-035484.md) | [91.7](/filings/0000950170-23-058814.md) | [91.4](/filings/0000950170-24-052085.md) | [91.5](/filings/0000950170-24-089248.md) | [91.2](/filings/0000950170-24-119044.md) | [92.0](/filings/0000950170-25-069294.md) | [92.0](/filings/0000950170-25-103160.md) | [92.2](/filings/0001193125-25-267062.md) | [92.0](/filings/0001193125-26-192508.md) | [90.4](/filings/0000950170-25-103160.md) | [90.6](/filings/0001193125-25-267062.md) | [90.9](/filings/0001193125-26-192508.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 92,211,777 at 2026-02-25, from the cover of the [10-K filed 2026-02-27](/filings/0001193125-26-078266.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.